One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study

Sun JK, Maturi RK, Boyer DS, Wells JA, Gonzalez VH, Tansley R, Hernandez H, Maetzel A, Feener EP, Aiello LP.
OPHTHALMOLOGY RETINA

Rapid and nearly complete suppression of plasma kallikrein activity with the oral inhibitor KVD900: results of a phase 1 study evaluating KVD900’s potential as a treatment for acute attacks of HAE

Maetzel A, Smith MD, Morten RM, Hampton SL, De Donatis GM, Murugesan NI, Rushbrooke LJ, Li L, Duckworth EJ, Feener EP, Yea C.

EAACI 2019

High plasma exposures of KVD900 achieved in First in Human study markedly inhibit plasma prekallikrein activation; early blockade of plasma kallikrein (PKa) may halt attacks in Hereditary Angioedema (HAE) by reducing contact system activation.

Duckworth EJ, Hampton SL, Li L, Murugesan N, Rushbrooke L, Smith M, Morten R, Maetzel A, Yea C, and Feener EP.

C1-INHIBITOR WORKSHOP 2019

Novel oral plasma kallikrein (PKa) inhibitors KV998052 and KV998054 ameliorate VEGF-induced retinal thickening in a murine model of retinal edema.

Murugesan N, Clermont AC, Pethen SJ, Li L, Duckworth EJ, Hampton SL, and Feener EP.

ARVO 2019

KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic results from a Phase 1 Single Ascending Dose Study.

Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Duckworth E, Smith MD, Morten RM, Maetzel A, Yea CM and Feener EP.
AAAAI 2019